Eleven Therapeutics

4 open jobs

ScionxBio is engineering next-generation RNA medicines by combining synthetic chemistry and artificial intelligence to create xRNA, a platform for long-acting therapeutics. The company uses its proprietary TERA® engine—a closed-loop system combining deep-learning design, combinatorial assembly, high-throughput screening, and model retraining—to engineer molecules that sustain protein expression for weeks to months with lower immunogenic burden. A spinout from Eleven Therapeutics, ScionxBio operates across Cambridge (UK), Tel Aviv, and Cambridge (MA), with an initial focus on cardiometabolic disease.